Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting beta(2)-adrenoceptor agonists

被引:0
作者
Linden, A
Rabe, KF
Lofdahl, CG
机构
[1] GOTHENBURG UNIV, SAHLGRENS HOSP, DIV PULM MED, S-41345 GOTHENBURG, SWEDEN
[2] KRANKENHAUS GROSSHANSDORF, LANDESVERSICHERUNGANSTALT HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, D-22927 GROSSHANSDORF, GERMANY
关键词
airway smooth-muscle relaxation; beta(2)-adrenoceptor agonists; bronchodilator; duration of action; exosite; formoterol; microkinetic diffusion; salmeterol; BETA-ADRENOCEPTOR AGONISTS; AIRWAY SMOOTH-MUSCLE; GUINEA-PIG TRACHEA; BETA-2-ADRENOCEPTOR AGONIST; FUNCTIONAL ANTAGONISM; SALBUTAMOL; RELEASE; BAMBUTEROL; INVITRO; ASTHMA;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The mechanisms behind the long duration of bronchodilating action of the beta(2)-adrenoceptor agonists formoterol and salmeterol are only partially understood, This review compares pharmacological characteristics of long-acting versus short-acting beta(2)-adrenoceptor agonists in human and animal airways. Based upon the reviewed evidence, it is concluded that for beta(2)-adrenoceptor agonists, long duration of action may depend upon several factors, Both formoterol and salmeterol display a higher lipophilicity and have a higher affinity, selectivity, and potency than most short-acting agonists at the beta(2)-adrenoceptor. Of these factors, lipophilicity may prove to be one of the most important ones by determining the amount of drug entering into the cell membrane in the vicinity of the beta(2)-adrenoceptor. However, the receptor affinity, maximal relaxant effect (efficacy or intrinsic activity), potency, and receptor selectivity may also be of importance in determining how much beta(2)-adrenoceptor agonist must remain at the receptor for sustained action.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 53 条
[1]  
ADVENIER C, 1991, American Review of Respiratory Disease, V143, pA651
[2]  
ANDERSON G, 1993, EUR RESPIR J, V6, P590
[3]   WHY ARE LONG-ACTING BETA-ADRENOCEPTOR AGONISTS LONG-ACTING [J].
ANDERSON, GP ;
LINDEN, A ;
RABE, KF .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (03) :569-578
[4]  
ANDERSON GP, 1992, ROY SOC MED INT CONG, V194, P3
[5]   SALMETEROL, A NOVEL, LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST - CHARACTERIZATION OF PHARMACOLOGICAL ACTIVITY INVITRO AND INVIVO [J].
BALL, DI ;
BRITTAIN, RT ;
COLEMAN, RA ;
DENYER, LH ;
JACK, D ;
JOHNSON, M ;
LUNTS, LHC ;
NIALS, AT ;
SHELDRICK, KE ;
SKIDMORE, IF .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (03) :665-671
[6]  
BALL DI, 1987, BRIT J PHARMACOL, V90, pP746
[7]  
BALL DI, 1987, BRIT J PHARMACOL, V88, pP591
[8]   DIFFERENT EFFECTS OF SALMETEROL, FORMOTEROL AND SALBUTAMOL ON CHOLINERGIC RESPONSES IN THE FERRET TRACHEA [J].
BERGENDAL, A ;
LINDEN, A ;
LOTVALL, J ;
SKOOGH, BE ;
LOFDAHL, CG .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (07) :1478-1482
[9]  
BRADSHAW J, 1987, British Journal of Pharmacology, V92, p590P
[10]  
BRITTAIN R T, 1988, Journal of Pharmacy and Pharmacology, V40, p93P